×

DecisionDx®-SCC Scientific References

Ibrahim S, Kasprzak J, Hall M et al. Enhanced metastatic risk assessment in cutaneous squamous cell carcinoma with the 40-gene expression profile test. Future Oncology 2021. doi: https://www.futuremedicine.com/doi/10.2217/fon-2021-1277

 

Wysong, A, Newman J, Covington K et al. Validation of a 40-gene expression profile test to predict metastatic risk in localized high-risk cutaneous squamous cell carcinoma. JAAD 2021; 361-368. doi: https://www.jaad.org/article/S0190-9622(20)30704-0/fulltext

 

Arron S, Wysong A, Hall M, et al. Gene expression profiling for metastatic risk in head and neck cutaneous squamous cell carcinoma. Laryng Investig Oto 2022; 1-10. doi: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8823155/

 

Borman S, Wilkinson J, Meldi-Sholl L et al. Analytical validity of DecisionDx-SCC, a gene expression profile test to identify risk of metastasis in cutaneous squamous cell carcinoma (SCC) patients. Diagnostic Pathology 2022. doi: https://diagnosticpathology.biomedcentral.com/articles/10.1186/s13000-022-01211-w

Farberg A, Fitzgerald A, Ibrahim S et al. Current Methods and Caveats to Risk Factor Assessment in Cutaneous Squamous Cell Carcinoma (cSCC): A Narrative Review. Dermatol Ther 2022. doi: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8850485/

 

Au J, Hooper P, Somani AK et al. Clinical Utility of the 40-Gene Expression Profile (40-GEP) Test for Improved Patient Management Decisions and Disease-Related Outcomes when Combined with Current Clinicopathological Risk Factors for Cutaneous Squamous Cell Carcinoma (cSCC): Case Series. Dermatol Ther 2021. doi: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8850491/

 

Arron S, Blalock T, Guenther M, et al. Clinical considerations for integrating gene expression profiling into cutaneous squamous cell carcinoma management. JDD 2021; s5-s10. doi: https://jddonline.com/articles/clinical-considerations-for-integrating-gene-expression-profiling-into-cutaneous-squamous-cell-carci-S1545961621S005sX/

 

Farberg AS, Hall MA, Douglas L, et al. Integrating gene expression profiling into NCCN high-risk cutaneous squamous cell carcinoma management recommendations: Impact on patient management. Curr Med Res Opin 2020. doi:10.1080/03007995.2020.1763284.

 

Litchman GH, Fitzgerald AL, Kurley SJ, et al. Impact of a prognostic 40-gene expression profiling test on clinical management decisions for high-risk cutaneous squamous cell carcinoma. Curr Med Res Opin 2020. doi:10.1080/03007995.2020.1763283.

 

Teplitz R, Prado G, Litchman GB, Rigel DS. Impact of gene expression profile testing on the management of squamous cell carcinoma by dermatologistsJ Drugs Dermatol 2019;18:980-4.

SEER data release 2019.

 

Mansouri B, Housewright CD. The treatment of actinic keratoses— the rule rather than the exception. JAMA Dermatol 2017;153:1200.

SCCHCP-RiskId.svg

Order DecisionDx-SCC

For Information

Call: 866-788-9007

Podcast

A Review of the DecisionDx-SCC Clinical Validation Study in Future Oncology

by Dr. Sherrif F. Ibrahim

Enhanced Metastatic Risk Assessment in Cutaneous Squamous Cell Carcinoma with the 40-Gene Expression Profile Test: An Interview with the Lead Author of DecisionDx-SCC’s Validation Study.

Speaker: Sherrif F. Ibrahim, MD, PhD., Assistant Professor, Department of Dermatology, University of Rochester Medical Center

Video Webinar

An Introduction to DecisionDx–SCC by Dr. Jason Newman, UPenn

AHNS DecisionDx–SCC Webinar: Identifying the Risk of Metastasis in cSCC and cSCC-HN Patients

Speaker: Dr. Jason Newman, Professor of Otorhinolaryngology - Head and Neck Surgery, University of Pennsylvania

What's Next?

DecisionDx®-UM Overview

How Do You Get a
DecisionDx-SCC Test?

Scroll to Top